Abstract
Polycystic kidney disease (PKD) is one of the most common life-threatening genetic diseases. Jared J. Grantham, M.D., has done more than any other individual to promote PKD research around the world. However, despite decades of investigation there is still no approved therapy for PKD in the United States. In May 2014, the University of Kansas Medical Center hosted a symposium in Kansas City honoring the occasion of Dr. Grantham's retirement and invited all the awardees of the Lillian Jean Kaplan International Prize for Advancement in the Understanding of Polycystic Kidney Disease to participate in a forward-thinking and interactive forum focused on future directions and innovations in PKD research. This article summarizes the contributions of the 12 Kaplan awardees and their vision for the future of PKD research.
Keywords:
genetic renal disease; genetics and development; polycystic kidney disease.
Copyright © 2015 by the American Society of Nephrology.
Publication types
-
Congress
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Biomedical Research / trends*
-
Cilia / genetics*
-
Cilia / metabolism
-
Genes, Modifier
-
Humans
-
Kidney Tubules
-
Mechanistic Target of Rapamycin Complex 1
-
Microtubule-Associated Proteins / genetics
-
Microtubule-Associated Proteins / metabolism
-
Molecular Targeted Therapy
-
Multiprotein Complexes / metabolism
-
Phenotype
-
Polycystic Kidney, Autosomal Dominant / drug therapy
-
Polycystic Kidney, Autosomal Dominant / genetics*
-
Polycystic Kidney, Autosomal Dominant / pathology
-
Renal Insufficiency / prevention & control
-
Signal Transduction*
-
TOR Serine-Threonine Kinases / metabolism
-
TRPP Cation Channels / genetics*
-
TRPP Cation Channels / metabolism
Substances
-
Microtubule-Associated Proteins
-
Multiprotein Complexes
-
TRPP Cation Channels
-
TTC21B protein, human
-
polycystic kidney disease 1 protein
-
polycystic kidney disease 2 protein
-
Mechanistic Target of Rapamycin Complex 1
-
TOR Serine-Threonine Kinases